Boehringer Ingelheim to advance potential new treatment for geographic atrophy following ...
Boehringer Ingelheim and CDR-Life report positive Phase I results for BI 771716, an antibody fragment targeting geographic atrophy (GA), meeting safety endpoints. The companies plan to initiate Phase II trials in early 2025, aiming to preserve vision in GA patients, a severe form of AMD leading to irreversible vision loss. BI 771716's design allows optimized retinal penetration and efficacy potential.
Related Clinical Trials
Reference News
Boehringer Ingelheim and CDR-Life report positive Phase I results for BI 771716, an antibody fragment targeting geographic atrophy (GA), meeting safety endpoints. The companies plan to initiate Phase II trials in early 2025, aiming to preserve vision in GA patients, a severe form of AMD leading to irreversible vision loss. BI 771716's design allows optimized retinal penetration and efficacy potential.